Journal
GENES & DEVELOPMENT
Volume 20, Issue 10, Pages 1331-1342Publisher
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/gad.1413306
Keywords
HNSCC; head-and-neck-specific knockout; metastasis; ras; TGF beta RII; TGF beta 1
Categories
Funding
- NCI NIH HHS [U01 CA105491, CA79998, CA87849, R01 CA087849, CA105491, R01 CA079998] Funding Source: Medline
- NIDCR NIH HHS [DE015953, R01 DE015953] Funding Source: Medline
Ask authors/readers for more resources
The prognosis of head-and-neck squamous cell carcinoma (HNSCC) has not been improved in the past 20 years. Validation of HNSCC biomarkers for targeted therapy has been hindered by a lack of animal models mimicking human HNSCC at both the pathological and molecular levels. Here we report that overexpression of K-ras or H-ras and loss of transforming growth factor-P type 11 receptor (TGF beta RII) are common events in human HNSCC. Activation of either K-ras or H-ras in combination with TGF beta RII deletion from mouse head-and-neck epithelia caused HNSCC with complete penetrance, some of which progressed to metastases. These tumors displayed pathology indistinguishable from human HNSCCs and exhibited multiple molecular alterations commonly found in human HNSCCs. Additionally, elevated endogenous TGF beta 1 in these lesions contributed to inflammation and angiogenesis. Our data suggest that targeting common oncogenic pathways in tumor epithelia together with blocking the effect of TGF beta 1 on tumor stroma may provide a novel therapeutic strategy for HNSCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available